At least one radiologist is tired of ED physicians asking 20 questions after every scan. Do you share his pain?
I have this conversation at least once a year:
“Hi, it’s Dr. Smith from the ED. Just wanted to follow up on that abdominal CT we ordered on Jane Doe.”
“Oh, yes…I signed that report awhile ago. Normal scan.”
“It’s normal? Because she had right lower quadrant pain.”
“Yeah, I saw that in the clinical history…nothing to account for the pain.”
“No appendicitis?”
“No, appendix looks totally normal.”
“No abscess? No obstruction?”
“Nope, nothing-normal study.”
“No colitis, nothing like that?”
“No. Normal study.”
“Hmm. No ovarian cyst or other badness in the adnexa?”
“No. Nothing. Normal scan.”
“Nothing, huh? No stone in the kidney or ureter?”
If you’ve ever had the dubious pleasure of participating in one of these little exercises, you’ve surely found yourself considering some of the sarcastic replies that I have fought to suppress (thus far, successfully).
For instance:
“Oho! You got me…I was trying to keep the stone a secret. Can’t fool you, can I?”
“Well, yes, there’s appendicitis since you asked, but aside from that the study’s normal.”
“No, when I said ‘normal,’ I meant it. But don’t let that stop you-there are at least six more diagnoses in the differential for this patient’s clinical history! Can you name them all?”
“I’m sorry, you’ve already used up your twenty questions for this patient; I have to move on to the other ten STAT full-body scans you ordered.”
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.